Glucagon-like peptide-1 agonist

From Wikipedia, the free encyclopedia
Jump to: navigation, search

Glucagon-like peptide-1 agonists (GLP-1 agonists) are a class of drugs for the treatment of type 2 diabetes.[1] Known as the "incretin mimetics".

One of their advantages over older insulin secretagogues, such as sulfonylureas or meglitinides, is that they have a lower risk of causing hypoglycemia.[2]

There is some concern over the safety profile of these drugs due to proliferative effects in the pancreas [3]

Licensed GLP-1 agonists:

Under investigation: [1]